We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Tart Cherry Juice in Reducing Muscle Injury and Biomarkers of Muscle Damage Among Healthy Adults

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01547949
First Posted: March 8, 2012
Last Update Posted: August 10, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Cherry Research Committee
Information provided by (Responsible Party):
Kerry Kuehl, Oregon Health and Science University
  Purpose
The purpose of this study is to assess the effects of tart cherry juice to reduce serum biomarkers of inflammation and reduce muscle soreness in healthy adults who undergo a bout of controlled eccentric exercise.

Condition Intervention Phase
Inflammation Pain Dietary Supplement: tart cultivar Montmorency cherry juice Dietary Supplement: placebo cherry fruit drink Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Tart Cherry Juice in Reducing Muscle Injury and Biomarkers of Muscle Damage Among Healthy Adults

Further study details as provided by Kerry Kuehl, Oregon Health and Science University:

Primary Outcome Measures:
  • Lactate [ Time Frame: duration of intervention, average of 18 days per participant ]
    Primary outcomes include measurement of serum and plasma biomarkers that provide a generalized measurement of inflammatory activity; these include Creatine Kinase (CK), Aspartate aminotransferase (AST), Lactate dehydrogenase (LDH), and lactate.

  • Creatine Kinase [ Time Frame: duration of intervention, average of 18 days per participant ]
    Primary outcomes include measurement of serum and plasma biomarkers that provide a generalized measurement of inflammatory activity; these include Creatine Kinase (CK), Aspartate aminotransferase (AST), Lactate dehydrogenase (LDH), and lactate.

  • Aspartate aminotransferase [ Time Frame: duration of intervention, average of 18 days per participant ]
    Primary outcomes include measurement of serum and plasma biomarkers that provide a generalized measurement of inflammatory activity; these include Creatine Kinase (CK), Aspartate aminotransferase (AST), Lactate dehydrogenase (LDH), and lactate.

  • Lactate dehydrogenase [ Time Frame: duration of intervention, average of 18 days per participant ]
    Primary outcomes include measurement of serum and plasma biomarkers that provide a generalized measurement of inflammatory activity; these include Creatine Kinase (CK), Aspartate aminotransferase (AST), Lactate dehydrogenase (LDH), and lactate.


Secondary Outcome Measures:
  • Secondary outcomes includes measurement of physical symptoms of exercise-induced muscle damage and soreness as measured by a muscle myometer. [ Time Frame: duration of intervention, average of 18 days per participant ]

Estimated Enrollment: 15
Study Start Date: March 2012
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: tart cherry juice Dietary Supplement: tart cultivar Montmorency cherry juice
Placebo Comparator: cherry flavored fruit drink Dietary Supplement: placebo cherry fruit drink

Detailed Description:
Numerous antioxidant and anti-inflammatory agents have been identified in tart cherries, and a study among healthy, non-exercising individuals demonstrated that tart cherries decreased post-exercise weakness and muscle pain. The purpose of this study is to assess the analgesic and myoprotective effects of tart cherry juice among healthy subjects in a randomized, placebo controlled, double-blind, crossover design trial. Fifteen healthy individuals will perform a bout of eccentric elbow flexion contractions (2 x 10 near maximum), and will then ingest 10 fl oz of a cherry juice or a placebo juice twice a day for four days, beginning immediately post exercise. Before and after exercise, and for three days following the eccentric exercise, blood will be drawn to measure serum biomarkers of muscle damage and muscle soreness will be recorded. The protocol will be repeated after a 9-10 day washout period with subjects consuming the alternative juice for the second trial. The opposite arm will perform the eccentric exercise for the second bout to avoid the repeated bout protective effect. The study's outcomes are 1) to assess changes in serum biomarkers of muscle damage, and 2) to assess changes in muscle soreness.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • no regular upper body strength training
  • no elbow flexor pain, no history of elbow or shoulder injury
  • ability and willingness not to take any anti-inflammatory or pain relieving drugs during the course of the study, not to seek any other treatment for any symptoms of muscle damage directly resulting from the exercises performed as part of the study, and not to exercise their upper extremities during the study.

Exclusion Criteria:

  • individuals who have used or are using antiepileptic drugs for pain, acupuncture, or transcutaneous electrical nerve stimulation within 3 weeks before enrollment
  • recent use (within 5 half-lives) of topical medications/anesthetics, muscle relaxants, tender point anesthetic injections within 2 months
  • systemic steroid use within 3 months
  • any investigational drug/device use in the prior 30 days
  • individuals who have Type 1 or Type 2 Diabetes
  • individuals who are pregnant
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01547949


Locations
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University
Cherry Research Committee
Investigators
Principal Investigator: Kerry S Kuehl, MD, DrPH Oregon Health and Science University
  More Information

Responsible Party: Kerry Kuehl, Associate Professor, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT01547949     History of Changes
Other Study ID Numbers: e7220
First Submitted: February 24, 2012
First Posted: March 8, 2012
Last Update Posted: August 10, 2012
Last Verified: August 2012

Keywords provided by Kerry Kuehl, Oregon Health and Science University:
pain
inflammation
muscle damage

Additional relevant MeSH terms:
Inflammation
Pathologic Processes